| ²é¿´: 604 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
06113021zjh½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÈóɫһ¾ä»°
|
||
|
Âé·³Ó¢ÓïºÃµÄ°ïæ¿´¿´ÏÂÃæÕâ»°ÓÐûÓÐʲôÎÊÌ⣬»ò°ïæ¸Äд£¬Ð»Ð»£¡ It is possible that A may improve non-bone metastasis-free survival for estrogen positive patients involve a mechanism independent of osteoclast mediated, but might have no effect on tumors outside of bone for estrogen negative patients. |
» ²ÂÄãϲ»¶
²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
081700ѧ˶£¬323·Ö£¬Ò»Ö¾Ô¸Öйúº£Ñó´óѧÇóµ÷¼ÁѧУ
ÒѾÓÐ15È˻ظ´
295Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸9²ÄÁÏѧ˶297ÒѹýÁù¼¶Çóµ÷¼ÁÍÆ¼ö
ÒѾÓÐ10È˻ظ´
312Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ12È˻ظ´
Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶
ÒѾÓÐ8È˻ظ´
¹¤¿Æ277·ÖÇóµ÷¼Á²ÄÁÏ
ÒѾÓÐ5È˻ظ´
µç×ÓÐÅÏ¢µ÷¼Á½»²æÑ§¿ÆÓÐÍÆ¼öÂð
ÒѾÓÐ9È˻ظ´
²ÄÁϹ¤³Ìר˶Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
06113021zjh: ½ð±Ò+10, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-11-19 22:44:59
06113021zjh: ½ð±Ò+10, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-11-19 22:44:59
|
Is this about Selective Estrogen Receptor Modulators (SERMs)? 1¡¢I believe you are talking about estrogen receptor, not estrogen; 2¡¢"mediated" is not required in your sentence. 3¡¢others as shown in CAPITALS in the revised sentence. It is possible that A improves non-bone metastasis-free survival for estrogen RECEPTOR (ER) positive patients, involving a mechanism independent of osteoclast PATHWAY, but has no effect on tumors outside of bone for estrogen RECEPTOR negative patients. |
2Â¥2014-11-19 22:29:36
06113021zjh
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 15 (СѧÉú)
- ½ð±Ò: 2060.9
- É¢½ð: 20
- ºì»¨: 1
- Ìû×Ó: 343
- ÔÚÏß: 229.6Сʱ
- ³æºÅ: 1866823
- ×¢²á: 2012-06-22
3Â¥2014-11-19 22:44:29














»Ø¸´´ËÂ¥